Ind Swift Laboratories Profile
Key Indicators
- Authorised Capital ₹ 60.00 Cr
- Paid Up Capital ₹ 59.09 Cr
- Company Age 30 Year, 27 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1,673.72 Cr
- Satisfied Charges ₹ 3,434.74 Cr
- Revenue Growth 15.09%
- Profit Growth 843.92%
- Ebitda 14.20%
- Net Worth 6.76%
- Total Assets -0.81%
About Ind Swift Laboratories
Ind Swift Laboratories Limited (ISLL) is a leading Public Limited Indian Non-Government Company incorporated in India on 04 January 1995 and has a history of 30 years. Its registered office is in Chandigarh, Chandigarh, India.
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 532305 and on the National Stock Exchange(NSE) under INDSWFTLAB.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 60.00 Cr and a paid-up capital of Rs 59.09 Cr.
The company currently has active open charges totaling ₹1,673.72 Cr. The company has closed loans amounting to ₹3,434.74 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Ind Swift Laboratories Limited India are Gagan Aggarwal as CFO and Pardeep Verma as Company Secretary. Navrattan Munjal, Sahil Munjal, Sri Sharma, and Five other members serve as directors at the Company.
Company Details
- Location
Chandigarh, Chandigarh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
L24232CH1995PLC015553
- Company No.
015553
- Stock Symbol
BSE : 532305 NSE : INDSWFTLAB
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
04 Jan 1995
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Listed
- ROC Code
Roc Chandigarh
Industry
What products or services does Ind Swift Laboratories Limited offer?
Ind Swift Laboratories Limited offers a wide range of products and services, including Common Disease Medicines, Pharmaceutical Tablets, Pharma Ingredients & Raw Materials, API Intermediate, Thyroxine Sodium Tablets, Antipyretic and Analgesic API, Chemical Reagents & Catalysts, Organic Compounds, TB, Tumor & Cancer Drugs, Anti Cancer Injection.
Who are the key members and board of directors at Ind Swift Laboratories?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Navrattan Munjal  | Managing Director | 04-Jan-1995 | Current |
| Gagan Aggarwal | CFO | Current | |
| Pardeep Verma | Company Secretary | Current |
Board Members (7)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sri Sharma | Director | 31-Aug-2009 | Current |
| Sahil Munjal | Whole-Time Director | 13-Feb-2020 | Current |
| Rishav Mehta | Whole-Time Director | 23-Mar-2010 | Current |
| Neerja Chathley | Director | 10-May-2019 | Current |
| Rajinder Gupta | Director | 23-Jun-2021 | Current |
| Ashwani Vig | Director | 31-Dec-2014 | Current |
Financial Performance of Ind Swift Laboratories.
Ind Swift Laboratories Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 15.09% increase. The company also saw a substantial improvement in profitability, with a 843.92% increase in profit. The company's net worth moved up by a moderate rise of 6.76%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ind Swift Laboratories?
In 2023, Ind Swift Laboratories had a promoter holding of 42.01% and a public holding of 58.00%. The company had 2 Subsidiaries. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Ind Swift LimitedNavrattan Munjal, Rishav Mehta and 1 more are mutual person
Mjm Remedies Private LimitedNavrattan Munjal and Himanshu Jain are mutual person
- Essix Biosciences Limited
Navrattan Munjal, Rishav Mehta and 1 more are mutual person
- Nimbua Greenfield (Punjab) Association
Navrattan Munjal is a mutual person
- Mohali Green Environment Private Limited
Navrattan Munjal is a mutual person
- Fortune (India) Constructions Limited
Sahil Munjal, Pardeep Verma and 1 more are mutual person
Charges (Loans)
₹1,673.72 Cr
₹3,434.74 Cr
Charges Breakdown by Lending Institutions
- Idbi Trusteeship Services Limited : 808.83 Cr
- Others : 659.94 Cr
- Edelweiss Asset Reconstruction Company Limited : 90.00 Cr
- Bank Of India : 65.25 Cr
- Idbi Bank Limited : 45.00 Cr
- Others : 4.70 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Aug 2023 | Axis Bank Limited | ₹1.70 Cr | Open |
| 21 Jun 2019 | Idbi Trusteeship Services Limited | ₹808.83 Cr | Open |
| 05 Sep 2018 | Others | ₹75.44 Cr | Open |
| 05 Sep 2018 | Others | ₹424.50 Cr | Open |
| 24 Nov 2011 | Edelweiss Asset Reconstruction Company Limited | ₹40.00 Cr | Open |
How Many Employees Work at Ind Swift Laboratories?
Unlock and access historical data on people associated with Ind Swift Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ind Swift Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ind Swift Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
